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Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome
known tumor immune evasion mechanisms. Dengue is unique among viruses as primary infections carry lower
mortality than the common cold, but secondary infections carry significant risk of hypovolemic shock. While current
immuno-therapies rely on a single axis of attack, this approach combines physiological (hyperthermic reduction of
tumor perfusion), immunological (activation of effector cells of the adaptive and innate immune system), and
apoptosis-inducing pathways (sTRAIL) to destroy tumor cells. The premise of using multiple mechanisms of action in
synergy with a decline in the ability of the tumor cells to employ resistance methods suggests the potential of this
combination approach in cancer immunotherapy.
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Combining dendritic cell vaccination with the adjuvant ef-
fect of a strain of dengue virus may be a way to overcome
known tumor immune evasion mechanisms. Dengue is
unique among viruses as primary infections carry lower
mortality than the common cold, but secondary infections
carry significant risk of hypovolemic shock [1,2]. While
current immuno-therapies rely on a single axis of attack,
this approach combines physiological (hyperthermic re-
duction of tumor perfusion), immunological (activation of
effector cells of the adaptive and innate immune system),
and apoptosis-inducing pathways (sTRAIL) to destroy
tumor cells. The premise of using multiple mechanisms of
action in synergy with a decline in the ability of the tumor
cells to employ resistance methods suggests the potential
of this combination approach in cancer immunotherapy.
Recently, three new classes of tumor immunotherapeu-
tic agents have achieved clinical and regulatory success.
Amgen’s talimogene laherparepvec (OncoVexGM-CSF), a
recombinant oncolytic virus, has demonstrated clinical
responses and a favorable safety profile in advanced
melanoma, a challenging indication with significant un-
met needs [3]. Dendreon’s sipuleucel-T (Provenge™) for* Correspondence: bruce.lyday@primevax.com
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unless otherwise stated.prostate cancer, and Bristol-Meyers Squibb’s (BMS) ipi-
limumab (Yervoy™) won first-in-class FDA approval for
cancer vaccines and immune checkpoint blockade
agents. The very recent FDA approval of Keytruda, a
PD-1 blocking agent, was a promising addition to the
immuno-oncology targeting approaches [http://www.
fda.gov/NewsEvents/Newsroom/PressAnnouncements/
ucm412802.htm]. However, the high cost of these agents,
combined with high toxicity for Yervoy™ [4], and modest
survival benefit for Provenge™, have dampened the initial
enthusiasm [5,6]. Recently, BMS’s combination of a CTL-
4A blocking agent (Ipilimumab) [7] and a PD-1 blocking
agent (Nivolumab) [8] demonstrated superior response
rates [3]. However, although the spectrum of adverse
events observed among patients treated with the concur-
rent regimen was qualitatively similar to previous experi-
ence with nivolumab or ipilimumab monotherapy, the
rate of adverse events was higher among patients treated
with the combination therapy. These, and other studies,
have proven that dendritic cells (DC) can induce Ag-
specific cytotoxic T lymphocytes (CTL), and that check-
point inhibitors can break T-cell tolerance to self-peptides.
Another new immunotherapy strategy involves creating
chimeric antigen receptor (CAR) T-cells as an adoptive
cell therapy. These genetically modified T-cells have high
affinity for tumor antigens, and recent data points to theirThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ever, the solid tumors employing numerous immune eva-
sion mechanisms described below appear much more
resistant to CAR T-cell therapy.
All of the above technologies share a common weak-
ness in that they are attacking tumor cells along a single
axis of mechanism of action. They have shown that early
incomplete clinical responses to single-mechanism drugs
are often followed by relapse, due to the emergence of
resistant tumor clones [10]. These new technologies rely
primarily on CTL, using specific T-Cell receptors to
identify and kill tumor cells. Over time, resistant tumor
clones with low or absent major histocompatibility com-
plex (MHC) expression often emerge under selective
pressure by CTL [11]. High mutation rates allow tumor
cells to turn genes on and off at random, employing
multiple evasion mechanisms, thereby allowing them to
evade the CTL induced by modern immunotherapies
[12]. While researchers have identified the genotypic and
phenotypic profiles of CTL that can generate an effective
response in the patient, durable, complete responses re-
main rare [13]. Reviewing cases of spontaneous regres-
sion in the context of extended febrile infections may
hold critical clues for researchers in cancer immunother-
apy [14].
An ideal immunotherapeutic strategy would employ
multiple mechanisms to overcome all of the tumor im-
mune evasion mechanisms and resistance factors seen in
advanced tumors.
Spontaneous regression of cancer and the febrile effect
Spontaneous regression (SR) is a rare event in cancer [14].
A common factor in many cases is a systemic infection
leading to a prolonged high fever in excess of 39.5°C.
While melanomas and sarcomas are the two indications
representing the most SR, regressions are also observed inFigure 1 Sequence of events showing how immune responses to patbreast, lung, and other tumor types. In the 1880’s, Dr.
William Coley noticed that cancer patients with post-
surgical infections, usually with Erysipelas bacteria, had
improved outcomes over those who did not have such in-
fections [15]. His observations lead to preparation of
Coley’s Toxins, suspensions of Gram+ bacterial cell ex-
tracts, which caused high fever along with immune activa-
tion. These mechanisms of action could induce potent
immune responses, resulting in tumor regression, as out-
lined in Figure 1 [16].
Tumors, by virtue of their high mitotic and cellular
metabolic rates, are often oxygen deficient [17]. This
oxygen deficiency leads to higher utilization of anaerobic
pathways to generate adenosine triphosphate (ATP),
with the result of higher levels of lactate, and lower pH
within the cytoplasm and nucleus [18]. This effect is
seen as a gradient, with low-perfusion melanomas and
sarcomas most vulnerable, and oxygen-saturated lung
and CNS tumors most resistant to the effects of febrile
hypo-perfusion [18]. In addition, the tumor perfusion is
lower under febrile conditions, leading to a selective per-
ipheral blood network restriction to conserve oxygen to
the brain [19]. In doing so, the oxygen supply to the
tumor sites is reduced. Therefore, by targeting and eradi-
cating these low-perfusion tumor sites with high genetic
plasticity, it might be possible to achieve an enhanced
response to therapy [20].
The effect of these restrictions on the hypo-perfused
tumor sites is an increase of their already high rates of
glycolysis [18]. However, perfusion is restricted for both
afferent and efferent vessels toward and away from the
tumor, so lactate and other waste products accumulate,
leading to necrosis [18]. This effect is further com-
pounded by high levels of TNFα, released by the im-
mune system during acute infections [21]. TNFα is an
inflammatory cytokine with pleiotropic effects, includinghogens can impact the immune response to tumor cells.
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tosis-Inducing-Ligand) [21,22]. A major function of
TNFα is to bind with Platelet-Erythrocyte-Cellular-
Adhesion Molecule-1 (PECAM-1), opening gap junctions
in High Endotheliel Venules (HEV) [21]. Consequently,
activated lymphocytes adhere to, and squeeze through
the gap junctions in the openings of HEVs, allowing
them to engage pathogens and tumor cell targets [23].
While TNFα is an important cytokine in immunother-
apy, high levels of TNFα can result in capillary leak
syndrome, which, if unchecked, can lead to hypovol-
emic shock [1,24].
DNA microarray analyses have revealed that hun-
dreds of genetically distinct tumor clones may exist in a
single patient with advanced tumor [25]. There is a pat-
tern of negative correlation between O2 supply and
genetic mutation rates [20]. The majority of agents such
as cytotoxic drugs, antibodies, and small molecules, are
nearly always blood-borne, exerting a Darwinian selective
pressure to tumor clones that evade therapeutic mecha-
nisms [17]. Clones with the lowest perfusion rates have
both low drug exposure and high capacity to evade im-
mune system detection, making them resistant to con-
ventional therapies [17,20]. Fever hyperthermia takes
advantage of this situation, starving low-flow, resistant
clones with mutated phenotypes, leaving more genetic-
ally stable clones for elimination by activated lympho-
cytes and other arms of the immune system [26,27].
Combining fever with activation of CTL and lymphokine-
activated killer cells (LAK) could lead to higher response
rates [23].
As intracellular pathogens, viruses activate LAK and
CTL via a Type I gene signature pathway, e.g., IL-1b, IL-Figure 2 Dengue fever and mechanisms of the immune response to t2, IL-7, IL-12, IL-15, IFNα, IFNβ, IFNγ, and GM-CSF
[28]. This activity mimics the signature found in re-
sponders to cancer immunotherapy [27]. While numer-
ous approaches using oncolytic and recombinant viruses
as vectors for tumor antigens have been attempted, the
clinical results have been disappointing [29-32]. In light
of the progress and limitations made in these areas, the
dengue virus is presented as a potential alternative to
other virus-based therapeutic approaches.Dengue virus as an adjuvant to immunotherapy
Dengue viruses (DV) are small (40 nm) + strand RNA vi-
ruses of the Togaviridae family, subfamily flaviviridae,
Group B [33]. DV is unique in that secondary infections
carry significant risk of hypovolemic shock, while the
primary infections have lower death rates than the com-
mon cold virus [2,34].Natural course of dengue infections
Dengue Fever is an acute self-limiting febrile disease
with significant toxicities that are transient and self-
limiting in nature in >95% of primary infections [1]. The
mechanisms of the immune response to the Dengue
virus and fever generation are shown in Figure 2.
The virus infects white blood cells of monocyte/
macrophage/dendritic cell lineage [35,36] (Figure 2).
The infected cells produce interferons, interleukins,
and other factors which mediate both specific and non-
specific immune responses, including high fever, capil-
lary permeability, rash, joint pain, and elevations of
hepatic transferase enzymes [1,22,35,37] (Table 1 and
Figure 3).he virus. NS1: nonstructural protein 1.
Table 1 Cytokine levels induced by dengue virus
Cytokine Control Post-Adjuvant Increase Data type/Ref #
IL-1β 9.4 pg/ml 745 pg/ml 79X In vitro [35]
IL-2 2.1 U/ml 60.3 U/ml 29X In vivo [37]
IL-7 18 pg/ml 75 pg/ml 4.6X In vivo [38]
IL-12 Undetectable 270 pg/ml 270X In vivo [39]
IL-15 5.2 pg/ml 12-31 pg/ml 2-6X In vivo [40]
IFNα <6 U/ml 1600 U/ml 267X In vivo [41]
IFNγ <0.025 U/ml 0.95 U/ml 16X In vivo [37]
TNFα 3 pg/ml 210 pg/ml 70X In vivo [22]
TNFβ Undetectable To 605 pg/ml 600X In vivo [41]
GM-CSF 0.2 pg/ml 10.5 pg/ml 53X In vitro [42]
Figure 3 Course of Dengue Fever, Markers, Grading, and
Symptoms. (A) Laboratory diagnostic options in a patient with
suspected dengue infection, (B) Progression from Dengue Fever to
Dengue hemorrhagic fever (DHF) and (C) Timeline and course of
clinical signs and symptoms of Dengue.
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sult in activation of a TH1-type response of CD4
+ and
CD8+ helper-inducer and cytotoxic-effector CTL, which
is also an effective phenotype for tumor immunother-
apy [43,44]. Secondary infections activate a TH2-type
response, with corresponding higher levels of pro-
inflammatory cytokines [45,46]. Secondary infections
carry a higher risk of complications, including progres-
sion to Dengue Hemorrhagic Fever (DHF) [38,45]. The
proposed causes of the cytokine shift to TH2-type are
many, but a major factor appears to be the existence of
semi-neutralizing IgG directed against the E glycoprotein.
By binding to, but not fixing, complement for virion
destruction, these immune complexes are scavenged by
activated Macrophages with up-regulated FC receptors
[38]. This increases infection kinetics, leading to higher
levels of TNFα and IL-6, with a subsequent increase
min capillary permeability pre-disposing to hypovolemic
shock, especially in protein-malnourished children and
infants [1,46]. This phenomenon is termed the “Immune
Enhancement Theory.”
In addition to the above, there are other cases of
DHF/DSS, which occur in primary infections that the
Immune Enhancement Theory cannot explain. In some
of these cases, genetic influences on children with cer-
tain HLA haplotypes can lead them to be more suscep-
tible to DHF/DSS [24]. In other cases, many children
from low-income areas of Asia, Africa, and Central and
South America, lack protein that lead to low serum al-
bumin levels. This is often compounded by a lower Body
Mass Index, which provides a higher ratio of vessel sur-
face area to body mass. These children represent a set of
physiological risk factors for increased capillary perme-
ability predisposing to shock syndrome upon infection
with dengue [1]. Additionally, many of the parents ad-
minister aspirin or NSAID drugs to the children, aggra-
vating their plasma leakage.
In conclusion, the chances of DHF/DSS occurring dur-
ing a primary infection of a well-nourished adult in aclinical setting are very low. In a managed setting, most
cases of DHF/DSS can be resolved by prompt adminis-
tration of replacement fluids [47].
Detection of viral nucleic acid, nonstructural protein 1
(NS1), or IgM sero-conversion is a confirmatory finding
in patients with suspected DV infection (Figure 3).
Vaccine development and safety
A DV epidemic in Brazil had no reported deaths out of
17,440 confirmed cases [48]. A study of elderly Taiwanese
found that patients with various pre-existing cancers had
a reduced risk of severe DV infection, with an ORR of 0.9
[49]. Pre-existing organ failure, however, doubled the
mortality risk [49,50]. Therefore, the proper and safe
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on proper fluid balance [1,47].
Disease severity progression from uncomplicated den-
gue fever (grade 1) to dengue shock syndrome (grade 4)
(Figure 3b):
a. Dengue fever (DF)










x. Temporal occurrence with other cases
b. Progression from Dengue Fever to Dengue
hemorrhagic fever (DHF)
c. Dengue Hemorrhagic Fever (DHF)
i. DHF has all of the symptoms of Dengue Fever
plus:
ii. Rising hematocrit
iii. Rise in AST/ALT >3.5 ULN
iv. Other hemorrhagic signs.
d. Dengue Shock Syndrome (DSS)
i. Rapid / weak pulse, and narrow pulse pressure; or
ii. Manifestations of hypotension and cold, clammy
skin and restlessness
iii. DSS is treated with fluid replacement and
supportive care
e. Timeline and course of clinical signs and symptoms
of DV infection (Figure 3c)
Dengue and immunosuppression of cancer patients
The immune suppression seen in patients with advanced
cancer is a complex and dynamic process. It involves tol-
erance to the tumor antigens themselves, which are usu-
ally recognized as “self” by CTL [51]. Breaking this
tolerance can be achieved by high levels of TH1 cytokines,
which dengue infection induces [37,51]. An important dis-
tinction with DV is that the majority of toxicities are
immune-mediated [52]. Children, who develop a more
immune-competent systemic response, generally experi-
ence a more severe course of disease than adults [1,46].
An article on the dengue epidemic in Taiwan in 2002
listed only 1 serious adverse event (renal failure) among
26 elderly cancer patients with severe dengue [49]. The
authors concluded that cancer co-morbidity lowered risk
for severe dengue (ORR of 0.9), but pre-existing organ
failure doubled the mortality risk. Proper patient selection
and strict clinical monitoring of vital signs, especially fluid
and electrolyte balance, should mitigate this risk [47].The promise of DV as an immunostimulant
DV has many characteristics supporting its use as a potent
immune-stimulant in cancer immunotherapy. DV has af-
finity for immature B-lymphocytes and antigen-presenting
cells (APC) of monocyte/macrophage and DC lineage
[42]. The kinetics of dengue infection proceed in a linear
fashion: injection of >106 pfu/ml by Aedes mosquito bite,
then, a 4-5 day incubation, followed by a 5-day syndrome
characterized by sudden onset of high (to 40.5°C) fever,
myalgia, arthralgia, photophobia, and rash, followed by
complete recovery in the majority of cases [1]. By infect-
ing, but not killing, the APC, DV up-regulates their CD80
and CD83 expression, resulting in a pro-inflammatory
TH1 cytokine profile [53]. Primary DV infections induce a
TH1 type response with activated CD4
+ and CD8+ effector
T cells as well as LAK cells [37,40,54]. This type of re-
sponse is seen in patients having complete responses to
cancer immunotherapies (Table 2) [25,55].
Secondary dengue infections induce a TH2 type response
mainly due to preexisting titers of semi-neutralizing
IgG antibody [38,45,52]. Activated macrophages with
up-regulated Fc-receptors engulf these complexes but
become infected with the non-neutralized virus [36].
These infected macrophages secrete TNFα and TH2
type cytokines which suppress CTL and NK responses
and lead to greatly increased vascular permeability,
resulting in hemorrhage and shock (Figure 4) [52,65].
This cytokine storm follows a fever capable of restricting
blood supply in synergy with TNFα to the low-perfusion,
high-mutation rate clones with the most genetically un-
stable, and hence most dangerous characteristics [18,19].
In response, these low-perfusion clones may up-regulate
the hypoxia-induced genes such as Survivin, thus, becom-
ing more resistant to several therapeutic methods [20].
The DV-induced cytokine storm could enhance the effects
of a variety of cancer immunotherapy approaches as fol-
lows: (1) direct targeting of the tumor cells, (2) targeting
tumors in synergy with hyperthermia (TNFα), (3) expand-
ing anti-tumor effector CTL, or (4) inducing tumor-
reactive LAK or CIK cells, and (5) overcoming many of
the immune evasion mechanisms employed by the tumor
cells (Table 2) [43,66].
These immune evasion mechanisms are responsible
for the lack of efficacy seen with most immunotherapy
platforms [12,66]. As researchers come to understand
the cancer therapy area at a deeper level, it is apparent
that single-axis attacks play to cancer’s strengths of low
perfusion and high mutation rates [17,20]. Therefore, a
multi-pronged approach to cancer therapy is required
to address all the immune evasion methods. The high
levels of IFNα and IFNγ are capable of restoring Class I
MHC levels essential for CTL recognition and lysis
[67,68]. Additionally, using DV as an adjuvant to activate
many pathways working in synergy could support the
Table 2 Tumor immune evasion mechanisms and DV infection
Immune evasion Dengue counter-attack
Low levels of MHC on tumor cell prevent CTL recognition [11] Hi Interferon-γ raises MHC levels by up-regulating MHC gene expression [37,52]
Point mutations in Tumor Peptides prevent TCR binding [12] LAK/CIK cells target “escaped” tumor cells expressing aberrant peptides or MHC [40,56]
Tumor vessels lack factors for CTL attachment and trafficking [12] Hi [TNF-a] restores gaps by altering PECAM-1, restores ICAM-1/VCAM-1 expression and
P and E-selectins [22,57]
FasL can kill Fas+ CTL by triggering apoptosis [12] Hi [IL-6, 15] protects Fas+ CTL by up-regulating FLIP ligand [58,59]
HLA-G protects from NK Cells [12] Hi [IL-2,7,12,15 raise activation of NK [56,60]
Stromal barriers inhibit CTL [12] Hi [IFN-γ] activates Macrophages to M1 [36]
Myeloid-Derived Suppressor Cells, (MDSC) [61] iNKT Cells can decrease MDSC [61]
CTL inactivated by TGF-β [12] TH1 cytokines reactivate tolerant CTL [51,62]
Tumor PI-9 blocks CTL killing ([63] Hi [CD8] & ICAM-1 expression can restore low-avidity CTL recognition and lysis by
stabilizing weak interactions between TCR and MHC + self-peptide [64]
T-regulatory cells block CTL [61] Hi CD4Helper cells overcome CD4Reg cells [37,61]
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efficacy of the cancer immunotherapy [56,69].
The ability of DV to attach to, and infect endothelial
cells expressing Heparin-Sulfate Glycosaminoglycans
(HSPG) may address a crucial impediment to clinical
response to immunotherapy [57]. Effective immuno-
therapy requires both an activated CTL and successful
trafficking of these CTL into tumor sites. To accom-
plish this, HSPG are expressed at higher levels in melan-
oma metastatic lesions, and by infecting tumor vessels,
DV may interrupt perfusion and attract infiltrating DC
and CTL to tumor areas. After DV is attracted to the
tumor areas, infiltration then becomes critical, as a review
study found that 93.8% of melanoma samples showed no
P and E-Selectin expression on CD31+ vessels [70]. With
Dengue triggering a stronger immune response throughFigure 4 Mechanisms in protective TH1 responses and exacerbating TTNFα, P and E-Selectins are also upregulated, increas-
ing attachment rates for CTL, to allow them to infil-
trate the tumor areas. The tumor areas were also
deficient in ICAM-1 expression. Induction of activated
CTL that cannot traffic to or infiltrate tumor areas will
lead to a sub-optimal response. By helping to up-regulate
P and E selectins, as well as ICAM-1, Dengue may help
address the critical barrier to successful immunother-
apy [64].
Additional evidence of DV’s adjuvant potential can be
found by analyzing gene expression profiles of cancer pa-
tients [25]. During active immunotherapy, researchers
found that responding patients displayed a unique signa-
ture of immune-related genes. These include: Interferon-γ,
interferon-regulatory factor-1 (IRF-1)/STAT-1 pathway,
including expression of HLA Class I and II genesH2 responses.
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lysin) [71]. These genes represent the same pathways acti-
vated by acute allograft rejection. Interferon-regulatory
factor-2 (IRF-2) family genes, on the other hand, are fre-
quently up-regulated in non-responding lesions, and are
associated with chronic inflammation [27].
Primary DV infections induce a TH1 type response with
specific expression patterns favoring induction of potent
anti-tumor immune responses (Table 3). Another factor
to consider is the phenotype of the vaccine-induced ef-
fector CTL. Most immunotherapy strategies utilize self-
antigens in a neutral or TH2 cytokine environment, and
the vaccine-induced T cells often have a regulatory CD4
+CD25+ Foxp3+ profile that can degrade, rather than en-
hance, the tumor immune response [72-74]. IL-12 appears
to have a critical role in shifting DC polarity to TH1, and
DV induces high levels of this cytokine [75]. For optimum
DC therapy, large numbers of antigen-loaded DC must
traffic to the white pulp region of the spleen [76-78]. A
successful immunotherapy approach must be able to in-
duce specific and non-specific effector cells, possessing
the ability to overcome the immunosuppressive tumor
microenvironment [13,60]. The effector cells induced
during DV infection were found to express markers as-
sociated with effective anti-tumor immune responses
(Table 4) [79].
While properly activated effector cells of the adaptive
and innate immune systems are powerful immunother-
apy agents, they are subject to certain limitations.
Activation-Induced Cell Death (AICD) of CTL involvesTable 3 Gene expression changes in DV infection
Gene Symbol Function
IL-1beta IL-1β Inflammation
Interleukin-2 IL-2 T cell growth
Interleukin-12 CLMF/CLMF2 Shift to TH1 Cytokines
Interferon γ IFNG Up-regulate Class I MHC
CD8 antigen CD8β1 CTL Co-receptor
Inducible T cell
co-stimulatory ligand
ICOSLG Non-naïve T cell activation TH1
cytokines
Chemokine ligand 3 CCL3 T-cell activation Autoimmunity
Chemokine ligand 5 CCL5 T-cell localization
TRAIL TRAIL Apoptosis Induction
Interferon-protein-10 IP10 T cell activation, Localization
Granulysin GNLY Apoptosis Induction
Granzyme A GZMA Target cell lysis
MHC class II DRα HLA-DRA Antigen Presentation
MHC class II DPα1 HLA-DPα1 MHC peptide Display
MHC class I DPβ1 HLA-DPβ1 MHC peptide Display
ζ chain kinase ZAP70 TCR signal transductionup-regulation of Bax apoptosis-inducing gene, and
down-regulation of Bcl-2, which counteracts Bax [58,83].
High levels of IL-2 pre-dispose CTL to AICD, and al-
though Dengue Virus induces high levels of IL-15 to
counteract this pathway, the majority of CTL induced
during the proposed vaccine therapy will eventually die off
due to AICD [58,80]. Another limitation is the require-
ments for adequate levels of HLA and cognate tumor
antigen expression on tumor target cells [11]. DV in-
duces high levels of HLA expression through IFNα and
IFNγ [37,41].
Dengue as an apoptosis-inducing agent
An ideal combination immunotherapy would combine
physiological mechanisms with activated effectors of the
adaptive and innate immune system, plus an apoptosis-
inducing agent specifically targeted to tumor cells. TNF-
related apoptosis-inducing ligand (TRAIL) is a member
of the TNF superfamily of apoptosis-inducing agents,
also including Fas (CD95. TNF [82] TRAIL/Apo2L binds
to five TNF-family receptors on the cell surface: two of
these, DR4 and DR5, are capable of transducing an
apoptotic signal through the capsase-8 pathway when li-
gated with TRAIL [84]. The other three: decoy receptor-
1 and 2, and the osteoprotegerin receptor, are incapable
of inducing apoptotic signal and are thought to have a
competitive inhibitory function [82,85] (Figure 5).
Dengue Virus induces high levels (300 pg/ml) of sol-
uble TRAIL (sTRAIL) from a variety of cells including
γδCTL, activated M1 macrophages and plasmacytoid DCFold-increase during
DV Infection
Immunotherapy significance
9.80 [52] Fever, Vascular permeability [35]
3.97 [46] CTL growth, NK Activation [80]
2.20 [46] TH1 cytokine storm [55]
2.85 [46] CTL recognize HLA + peptide [11]
5.74 [52] Stabilizes MHC-TCR bond [68]
2.44 [52] Optimize response of CTL [25]
4.64 [52] Marker of vaccine response [25]
7.33 [52] T-cell attraction to tumor area [81]
42.0 [65] Induces Apoptosis in Tumor Cells [82]
46.0 [65] Levels correlate w/clinical outcome in
RCC [71]
4.90 [52] Induces Apoptosis [52]
4.61 [52] Effector CTL [25]
7.26 [52] Antigen Presentation [52]
4.58 [52] Antigen (Ag) Presentation [52]
2.72 [52] Antigen Presentation [52]
3.03 [52] Restores CTL signaling [52]
Table 4 Markers of activated lymphocytes in DV infection in vivo [40]
Marker Control Dengue fever Fold-Change Relevance
CD8+ CD44+62 L− 6.5 24 3.7 Effector/memory set/Traffic to inflamed tissue
CD4+ CD44 + CD62LLO 7.1 22.4 3.2 Helper/Traffic to Inflamed Tissue
HLA-DR+ (CD8) 5.8 12.5 2.2 Activation Marker
Tia-1 (CD8) 6.6 20.3 3.1 Cytolytic effector
VLA-4 CD8) 42.7 61.0 1.4 CTL trafficking to inflamed sites
ICAM-1 (CD8) 18.8 29.8 1.6 Cell adhesion
LFA-1 (CD8) 52.9 71.4 1.4 Binds to ICAM-1 on target, co-stimulation
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produce high levels of IFNα and membrane-bound
TRAIL, giving them a killer or kpDC designation [41].
The non-classical γδ CTL, when activated by DV and
West Nile Virus glycoproteins, secrete sTRAIL as their
mechanism of action (MoA) against a wide variety of
tumor cells [89,90]. While the precise amount of
sTRAIL required to induce apoptosis has wide variation
by tumor type, DR4/5 levels, and prior sensitization, the
high levels of sTRAIL and factors to reduce resistance
by Dengue may prove an effective mechanism of action
to complement the vaccine therapy [83,91,92].
TRAIL has represented an attractive targeting ap-
proach, as it is capable of killing a wide range of tumor
cells without harm to normal cells [84]. However, clin-
ical trials with TRAIL have met with little success, asFigure 5 Representation of Apo2L/TRAIL apoptotic pathway and its r
for non-commercial use [86].some cancer cells down-regulate DR4 and DR5 through
activation of the NF-κβ pathway, allowing resistance to
TRAIL [82]. Studies of melanoma lines showed an in-
crease in decoy receptor and decrease in DR4/5 expres-
sion as lesions progressed [85]. For TRAIL to effectively
induce apoptosis, tumor cells must be first sensitized by
exposure to cytokines and other factors which up-
regulate DR4/5 expression levels (Figure 6) [85].
DV activates multiple pathways known to help over-
come resistance to TRAIL-mediated apoptosis of tumor
cells. For example, DV replicates via a dsRNA inter-
mediate, and this complex, while assembling in the
Endoplasmic Reticulum, activates the TLR3 system
[83,94]. Increased expression of TLR3 leads to suppres-
sion of DR4/5 inhibitory pathways and subsequent in-
creases in TRAIL sensitivity [83]. In addition, DVelation to the NF-κβpathway. With permission from Springer Images
Figure 6 H & E staining for Death Receptors DR4 and DR5, compared to Decoys DcR1 and DcR2. In primary epithelial cells (top row), staining
of DR4/5 is greater then DcR1/2. In metastatic lesions, (bottom row), the relative expressions are reversed, conferring resistance to TRAIL-mediated
apoptosis. With permission from Springer Images for non-commercial use [93].
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tropic cytokine of the IL-6 family [95]. IL-27 acts to
up-regulate TLR3 signaling on melanoma cells, and re-
stores vulnerability to TRAIL-mediated apoptosis [83].
DV infection also stimulates the inducible Nitric Oxide
(iNOS) pathway [91], which plays a pivotal role in re-
modeling vessel diameter and architecture during infec-
tion. iNOS is released by Macrophages and endothelial
cells exposed to stimuli like Lipopolysaccharide binding
protein (LPS) and IFNγ NO also sensitizes tumor cells
to sTRAIL by inhibiting both NF-κΒ and the DR5 tran-
scription repressor Yin Yang 1 [92]. This correlates with
restoring sensitivity to TRAIL-mediated apoptosis by
sTRAIL, or effector cells: γδCTL and kpDC, expressing
membrane-bound TRAIL receptors [41,88,96].
DV also activates IFNβ, a multifunctional cytokine
with a 10-fold higher affinity for the same receptor as
IFNα [94]. IFNβ has similar antiviral properties in sup-
pressing transcription of viral RNA, but is much more
potent than IFNα in inducing apoptosis in tumor cells
[97]. NO and IFNβ could act in a synergistic fashion
during dengue infection. These molecules may work in
tandem to overcome resistance to apoptosis mediated by
the high levels of sTRAIL induced by M1 macrophages,
pDC, and δγ CTL [82].
Conclusions
In summary, the multiple DV-induced pathways over-
coming the resistance to TRAIL-mediated apoptosis of
tumor cells, combined with the high levels of TRAIL
expressed on dengue effectors and sTRAIL released,
could prove highly effective in eliminating tumor cells
able to survive the multiple physiologic and cellular ef-
fector arms of the therapy. Thus, the approach employs
not only multiple mechanisms of action, but entiresystems: physiological, immunological, and apoptotic
gene expression systems. A concentrated, coordinated
effort to attack tumors on multiple pathways in a syner-
gistic fashion could lead to higher response rates than
current approaches attacking tumors along a single-axis
pathway [98].
Primary DV infections allow a unique window of op-
portunity to employ both adaptive and innate immune
responses directed against tumor cells, combined with
physiological and death-receptor gene pathways. The
fever and TNFα work in synergy to eliminate the most
dangerous cells: those with high mutation rates and low
perfusion; these tumor cells are the most resistant to
systemic cancer therapies. TNFα also helps to remodel
tumor microvasculature lacking the factors needed for
CTL attachment and extravasation: P and E-Selectins,
ICAM-1, VACM-1. Up-regulated Heparin Sulfate Gly-
cosaminoglycan expression should increase virus infec-
tion in these areas. The high levels of TH1-type
cytokines result in maximum stimulation of effector cells
of both the innate and the adaptive immune systems.
Simultaneously, these cytokines help to overcome the
immune evasion and resistance mechanisms employed
by the tumor cells. As a final mechanism of action, den-
gue virus induces high levels of sTRAIL, an apoptosis-
inducing ligand binding to Death Receptor 4 (DR4) and
Death Receptor 5 (DR5), expressed on tumor and virus-
infected cells. While some tumor cells are resistant to
sTRAIL, dengue also activates factors capable of over-
coming this resistance to sTRAIL-mediated apoptosis.
A start-up biotechnology company (PrimeVax, LLC) has
patented the use of dengue as a cancer immunotherapy
agent in conjunction with autologous, tumor-lysate-
pulsed dendritic cells. Dr. Duane Gubler, D.Sc., has pro-
vided PrimeVax LLC with a DEN-2 strain #1710 isolated
Lyday et al. Journal of Translational Medicine  (2015) 13:3 Page 10 of 12during a Puerto Rican epidemic. This outbreak had 9,540
suspected cases of DV, with one suspected, but no con-
firmed deaths due to the virus [99]. PrimeVax is currently
planning a Phase I trial in advanced melanoma, combining
autologous tumor lysate-pulsed DC with DV as an adju-
vant. The results from this trial may unlock some of the
secrets of tumor immune evasion that have been obstacles
to achieving better clinical responses.
Some future issues that need to be further explored
include:
1. Although epidemiological and experimental data for
DV infections appear to have an acceptable safety
profile, only a clinical trial will provide the data
required to properly evaluate the actual efficacy and
safety of this novel approach.
2. It is possible that the cytokine release induced by
the innate stimulator dengue virus will cause
endothelial leakage similar to the side effect that has
been seen in CAR-T trials and IL-2. However, the
dengue cytokine storm is an intrinsic factor, and is
therefore subject to internal regulation pathways
such as increased levels of IL-4 and IL-10 during the
recovery phase. Bolus IL-2 and CAR-T cells are
extrinsic factors which are more difficult to regulate
by internal feedback/inhibition loops. This difference
may lead to a lower rate of serious effects related to
endothelial leakage, especially with careful monitoring
of BP, hematocrit, and fluid balance.
3. PrimeVax is preparing to file an IND with the FDA
Center for Biologics Evaluation and Research
(CBER) for a small Phase 1 trial using their
approach on advanced melanoma patients
progressing on current therapies.
4. If this approach has a favorable safety and efficacy
profile, PrimeVax intends to expand their indication
targets to include breast, prostate, and brain cancer,
as well as other solid tumors and leukemias/
lymphomas.
5. The principles of PrimeVax’s therapy can be applied
to any type of solid tumor or leukemia/lymphoma
by altering the antigens used to pulse the dendritic
cells.
6. Whole tumor cell lysates can be utilized in order to
present the full range of class-I and class II peptides
to CTL, as well as to employ epitope spreading
principles to target immune-escape variants.Competing interests
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